7.49
전일 마감가:
$7.46
열려 있는:
$7.19
하루 거래량:
942.25K
Relative Volume:
1.30
시가총액:
$574.53M
수익:
-
순이익/손실:
$-209.96M
주가수익비율:
-2.3703
EPS:
-3.16
순현금흐름:
$-176.27M
1주 성능:
-23.18%
1개월 성능:
-34.93%
6개월 성능:
-33.89%
1년 성능:
+1.77%
레플리뮨 Stock (REPL) Company Profile
명칭
Replimune Group Inc
전화
(781) 222-9600
주소
500 UNICORN PARK, WOBURN, MA
REPL을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
REPL
Replimune Group Inc
|
7.49 | 574.53M | 0 | -209.96M | -176.27M | -3.16 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
레플리뮨 Stock (REPL) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-08-28 | 개시 | ROTH MKM | Buy |
2023-04-17 | 재개 | Piper Sandler | Overweight |
2021-11-19 | 개시 | Piper Sandler | Overweight |
2021-10-15 | 재개 | BTIG Research | Buy |
2020-11-17 | 개시 | BTIG Research | Buy |
2020-11-02 | 개시 | Jefferies | Buy |
2020-10-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2020-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2020-05-05 | 개시 | Barclays | Overweight |
2019-09-04 | 개시 | ROTH Capital | Buy |
2019-07-23 | 개시 | Chardan Capital Markets | Buy |
2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
2019-07-08 | 개시 | H.C. Wainwright | Buy |
2019-04-25 | 개시 | Wedbush | Outperform |
2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2018-08-14 | 개시 | JP Morgan | Overweight |
2018-08-14 | 개시 | Leerink Partners | Outperform |
모두보기
레플리뮨 주식(REPL)의 최신 뉴스
Teacher Retirement System of Texas Takes $189,000 Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Trading Down 7.6%What's Next? - MarketBeat
SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy - The Manila Times
Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Swiss National Bank - Defense World
Charles Schwab Investment Management Inc. Has $6.16 Million Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Victory Capital Management Inc. Purchases Shares of 44,880 Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Bank of New York Mellon Corp Increases Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Holdings Cut by AlphaQuest LLC - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives $19.43 Average Price Target from Analysts - Defense World
Arizona State Retirement System Invests $156,000 in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Financial Metrics Check: Replimune Group Inc (REPL)’s Ratios for Trailing Twelve Months - The Dwinnex
Replimune Group Appoints New Director, Grants Stock Options By Investing.com - Investing.com Australia
Replimune Group Appoints New Director, Grants Stock Options - Investing.com
Replimune Group Appoints Michael Goller To Board, Increases Board Size To Ten -March 07, 2025 at 05:04 pm EST - Marketscreener.com
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) -March 07, 2025 at 04:11 pm EST - Marketscreener.com
Rhumbline Advisers Grows Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs - Bain Capital
New York State Common Retirement Fund Purchases 31,231 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
JPMorgan Chase & Co. Increases Replimune Group (NASDAQ:REPL) Price Target to $18.00 - MarketBeat
Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00 - Defense World
Replimune Group (NASDAQ:REPL) Stock Price Up 6.1%What's Next? - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Receives $19.29 Average Price Target from Brokerages - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Short Interest Update - MarketBeat
Replimune's SWOT analysis: oncolytic immunotherapy stock poised for FDA approval - Investing.com
Possible Bearish Signals With Replimune Group Insiders Disposing Stock - Simply Wall St
Leerink Partnrs Predicts Weaker Earnings for Replimune Group - Defense World
FY2025 EPS Estimates for Replimune Group Lowered by Wedbush - MarketBeat
Replimune Group (NASDAQ:REPL) Announces Quarterly Earnings Results - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock - MarketBeat
Replimune stock target raised to $22 at H.C. Wainwright - MSN
Navigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global Risks - MSN
Replimune stock target raised to $22 at H.C. Wainwright By Investing.com - Investing.com Australia
Replimune: A Misunderstood Contender In Oncolytics (NASDAQ:REPL) - Seeking Alpha
Wedbush Raises Replimune Group's Price Target to $19 From $16, Keeps Outperform Rating - Marketscreener.com
Replimune Group Inc. (REPL) reports earnings - Quartz
Replimune Group, Inc. SEC 10-Q Report - TradingView
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
FDA Fast-Tracks Replimune's Melanoma Treatment as Cash Reserves Hit $536M in Q3 Report - StockTitan
Top Wealth Group Holding Ltd (TWG)’s financial ratios: A comprehensive overview - The Dwinnex
Metric Analysis: Nvni Group Ltd (NVNI)’s Key Ratios in the Limelight - The Dwinnex
Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
레플리뮨 (REPL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):